Aplastic anemia is a rare, life-threatening bone marrow failure syndrome characterized by pancytopenia and bone marrow hypocellularity (<25%), resulting from immune-mediated destruction of hematopoietic stem cells. [1-3] An aplastic crisis presents acutely with severe cytopenias leading to hemorrhage, overwhelming infection, and/or symptomatic anemia requiring emergent stabilization. The 2-year mortality with supportive care alone in severe disease approaches 80%. [4]
1. History
- Key HPI questions: Onset and duration of fatigue, dyspnea, bleeding (gingival, epistaxis, petechiae, menorrhagia), fevers, recurrent infections, weight loss
- Symptom characterization: Progressive fatigue, exertional dyspnea, easy bruising, mucosal bleeding, pallor
- Timing/triggers: Preceding viral illness (especially hepatitis 2–3 months prior), new medication exposure, chemical/toxin exposure (benzene, pesticides, radiation) [5-6]
- Associated symptoms: Fever, sore throat, oral ulcers, melena, hematuria
- Important negatives: No bone pain (argues against leukemia), no lymphadenopathy or hepatosplenomegaly (argues against infiltrative process), no B-symptoms typical of lymphoma
2. Alarm Features
- ANC <0.5 × 10⁹/L (severe) or <0.2 × 10⁹/L (very severe) — high risk of fatal infection [4][7]
- Platelets <10–20 × 10⁹/L — risk of spontaneous intracranial or GI hemorrhage
- Active uncontrolled bleeding (GI, intracranial, pulmonary)
- Febrile neutropenia (temperature ≥38.3°C with ANC <0.5 × 10⁹/L) — treat as oncologic emergency
- Signs of sepsis: Hemodynamic instability, altered mental status, lactic acidosis
- Retinal hemorrhages on fundoscopy
- Hepatitis-associated aplastic anemia (HAAA): Severe cholestatic hepatitis preceding pancytopenia by ~3 weeks, especially in young males [5][8-9]
3. Medications
- Causative/contributing medications: [5][10-12]
- Antiepileptics: carbamazepine, phenytoin, felbamate
- Antibiotics: chloramphenicol, sulfonamides, trimethoprim-sulfamethoxazole, linezolid
- NSAIDs: indomethacin, diclofenac, phenylbutazone
- Antirheumatic: gold salts, D-penicillamine, methotrexate
- Antithyroid: methimazole, propylthiouracil
- Others: colchicine, allopurinol, azathioprine
- Chemotherapeutics: temozolomide, busulfan, fludarabine, carboplatin
- Checkpoint inhibitors: nivolumab, pembrolizumab [7][10]
- Contraindicated medications: Avoid further myelosuppressive agents; avoid IM injections if thrombocytopenic; avoid aspirin/NSAIDs (platelet dysfunction)
- Caution: Minimize unnecessary medications; use irradiated, leukoreduced, CMV-safe blood products if transplant candidate [13]
4. Diet
- Neutropenic diet (low-microbial diet) for patients with ANC <0.5 × 10⁹/L: Avoid raw meats, unpasteurized dairy, unwashed raw fruits/vegetables
- Adequate hydration — especially if febrile or receiving IV antibiotics
- Iron-rich foods are generally not helpful (anemia is production-based, not deficiency-based); iron overload from transfusions is a long-term concern
- Folate supplementation may be considered to support any residual erythropoiesis, though deficiency should be ruled out as an alternative cause of pancytopenia [14]
5. Review of Systems
- Constitutional: Fatigue, malaise, weight loss, fevers, night sweats
- HEENT: Oral ulcers, gingival bleeding, epistaxis, visual changes (retinal hemorrhage)
- Cardiovascular: Palpitations, exertional dyspnea, chest pain (high-output failure from severe anemia)
- GI: Melena, hematochezia, abdominal pain, jaundice (hepatitis-associated AA)
- GU: Hematuria, menorrhagia
- Skin: Petechiae, purpura, ecchymoses, pallor
- Neuro: Headache, altered mental status (intracranial hemorrhage or CNS infection)
- MSK: Absence of bone pain (helps distinguish from leukemia)
6. Collateral History and Family History
- Collateral: Medication list review, occupational exposures (benzene, solvents, pesticides, radiation), recent travel, sick contacts, recent viral illness [6][15]
- Family history: Inherited bone marrow failure syndromes — Fanconi anemia (short stature, café-au-lait spots, thumb/radial anomalies), dyskeratosis congenita (nail dystrophy, oral leukoplakia, skin pigmentation), Shwachman-Diamond syndrome [15-16]
- Social context: Occupational chemical exposure, recreational drug use, HIV risk factors
7. Risk Factors
- Idiopathic (~50–70% of cases) [5]
- Viral infections: Hepatitis (non-A, non-B, non-C most common), parvovirus B19, EBV, CMV, HIV [9][17-18]
- Drug exposure: See Medications section above
- Chemical/toxin exposure: Benzene (industrial), pesticides, insecticides [6][19]
- Autoimmune diseases: Rheumatoid arthritis, SLE, eosinophilic fasciitis [12]
- Age: Bimodal distribution — peaks in young adults (15–25 years) and older adults (>60 years)
- Geography: Higher incidence in East Asia (~2–3× Western rates) [20]
- Pregnancy (rare association)
- PNH clone: Found in 10–20% of patients with aplastic anemia [3][21]
8. Differential Diagnosis
- Myelodysplastic syndrome (MDS): Most important mimic; may present with pancytopenia and hypocellular marrow; distinguished by dysplasia, cytogenetic abnormalities, and somatic mutations [22-24]
- Acute leukemia (AML/ALL): Blasts on peripheral smear or marrow; bone pain, lymphadenopathy, hepatosplenomegaly
- Hairy cell leukemia: Pancytopenia with splenomegaly, "fried egg" cells on smear
- Megaloblastic anemia (B12/folate deficiency): Macrocytosis, hypersegmented neutrophils; reversible with supplementation [14]
- HIV/AIDS: Can cause pancytopenia via marrow suppression
- Hemophagocytic lymphohistiocytosis (HLH): Fever, splenomegaly, hyperferritinemia, hypertriglyceridemia [7]
- Disseminated infections: Tuberculosis, histoplasmosis, leishmaniasis — marrow infiltration [25]
- Paroxysmal nocturnal hemoglobinuria (PNH): Overlaps with AA; hemolysis, thrombosis, pancytopenia [21][26]
- Myelofibrosis: Dry tap on aspirate, splenomegaly, leukoerythroblastic smear
- Copper deficiency: Especially post-gastric bypass or with zinc supplementation [13]
- Inherited bone marrow failure syndromes: Fanconi anemia, dyskeratosis congenita (especially in younger patients) [15-16]
9. Past Medical History
- Prior episodes of cytopenias or blood transfusions
- History of autoimmune disease (RA, SLE)
- Prior hepatitis or liver disease
- Prior chemotherapy or radiation therapy
- History of PNH
- Surgical history (splenectomy, gastric bypass)
- Chronic medications (especially those listed above)
- Transfusion history (important for iron overload assessment and HLA sensitization if transplant candidate)
10. Physical Exam
- Vital signs: Tachycardia, hypotension (hemorrhage/sepsis), fever (infection), tachypnea
- General: Pallor, ill-appearing
- Skin: Petechiae, purpura, ecchymoses, pallor of nail beds and conjunctivae
- HEENT: Oral ulcers, gingival bleeding, fundoscopic exam for retinal hemorrhages, scleral icterus (hepatitis-associated)
- Lymph nodes: Typically absent lymphadenopathy (presence suggests leukemia/lymphoma)
- Abdomen: Typically no hepatosplenomegaly (presence suggests alternative diagnosis such as leukemia, lymphoma, or PNH)
- Cardiac: Flow murmur (severe anemia), signs of high-output failure
- Neuro: Mental status changes (intracranial hemorrhage, CNS infection)
- Stigmata of inherited syndromes: Short stature, skeletal anomalies, café-au-lait spots, nail dystrophy (Fanconi anemia, dyskeratosis congenita) [15]
11. Lab Studies
- CBC with differential: Pancytopenia — low Hb, WBC, platelets; low reticulocyte count is a hallmark [21]
- Peripheral blood smear: Normocytic or macrocytic RBCs, no blasts, no dysplasia, no schistocytes
- Reticulocyte count: Depressed (reticulocyte production index <2)
- CMP: Hepatic function (hepatitis-associated AA), renal function
- LDH, haptoglobin, indirect bilirubin: Rule out hemolysis
- Iron studies, ferritin: Assess iron overload from transfusions; rule out iron deficiency
- B12, folate (RBC folate preferred), methylmalonic acid: Rule out megaloblastic anemia [13-14]
- Viral serologies: Hepatitis A/B/C, HIV, EBV, CMV, parvovirus B19 IgM/IgG (or PCR in immunocompromised) [17][27]
- Flow cytometry (FLAER): Screen for PNH clone — recommended at diagnosis [26]
- Blood type and screen, HLA typing: Perform early if transplant candidate [15]
- Coagulation studies: PT/INR, aPTT, fibrinogen (rule out DIC, assess coagulopathy)
- Blood cultures: If febrile
- Ferritin, triglycerides, fibrinogen: If HLH suspected
12. Imaging
- Chest X-ray: Baseline; evaluate for pneumonia in febrile neutropenic patients
- CT chest (without contrast if thrombocytopenic): If concern for invasive fungal infection (aspergillosis — halo sign, air crescent sign)
- Abdominal ultrasound: Assess spleen size (should be normal in AA; splenomegaly suggests alternative diagnosis); evaluate liver if hepatitis-associated
- CT head (non-contrast): If altered mental status or signs of intracranial hemorrhage
- Imaging is generally not diagnostic for aplastic anemia itself — diagnosis requires bone marrow biopsy
13. Special Tests
- Bone marrow aspirate and biopsy: Essential for diagnosis — hypocellular marrow (<25% cellularity) with fat replacement, absence of fibrosis, dysplasia, or infiltrative process [15][21]
- Cytogenetics (karyotype): Rule out MDS-associated abnormalities
- Molecular/NGS panel: Somatic mutations (PIGA, BCOR associated with better prognosis; RUNX1, ASXL1 associated with clonal evolution risk) [28]
- Chromosomal breakage testing (DEB/MMC): If Fanconi anemia suspected (especially age <40) [15]
- Telomere length testing: If dyskeratosis congenita suspected
- Germline genetic testing: If clinical features suggest inherited bone marrow failure [15]
Severity classification (modified Camitta criteria): [4][7]
- Severe AA: Bone marrow cellularity <25% PLUS at least 2 of: ANC <0.5 × 10⁹/L, platelets <20 × 10⁹/L, reticulocyte count <60 × 10⁹/L
- Very severe AA: Same as severe but ANC <0.2 × 10⁹/L
14. ECG
- Indications: Tachycardia, chest pain, severe anemia (Hb <7 g/dL), electrolyte abnormalities
- Expected findings: Sinus tachycardia, ST-T wave changes from anemia-related demand ischemia
- Dangerous patterns: ST elevation/depression (myocardial ischemia from severe anemia), arrhythmias from hyperkalemia (tumor lysis in rare cases of concurrent malignancy or transfusion-related)
15. Assessment
- Clinical summary: Aplastic anemia crisis represents acute decompensation of bone marrow failure with life-threatening cytopenias. The immediate threats are hemorrhage (from thrombocytopenia), infection/sepsis (from neutropenia), and symptomatic anemia (high-output cardiac failure). [4][29]
- Severity stratification: Non-severe vs. severe vs. very severe — drives treatment urgency and modality [4][7]
- Typical presentation: Insidious onset of fatigue, bleeding, and infections over weeks to months; crisis occurs when cytopenias reach critical thresholds
- Atypical presentations: Hepatitis-associated AA (jaundice preceding pancytopenia), isolated severe thrombocytopenia or neutropenia before full pancytopenia develops
- Complications: Invasive fungal infections (aspergillosis, candidiasis), bacterial sepsis, intracranial hemorrhage, transfusional iron overload, clonal evolution to MDS/AML (10–15% long-term) [3][28-29]
16. Treatment Plan
Initial stabilization (ED/acute care)
- ABCs, IV access, continuous monitoring
- Transfusion support:
- pRBC transfusion for symptomatic anemia or Hb <7 g/dL (use irradiated, leukoreduced products; CMV-safe if transplant candidate) [7][21]
- Platelet transfusion for active bleeding or platelets <10 × 10⁹/L (threshold may be higher with fever/infection)
- Avoid unnecessary transfusions to minimize HLA alloimmunization if transplant is being considered
- Febrile neutropenia protocol: Broad-spectrum antibiotics immediately (e.g., piperacillin-tazobactam, cefepime, or meropenem); add antifungal coverage if no response in 48–72 hours [21]
- Antimicrobial prophylaxis (for severe neutropenia): Fluoroquinolone (antibacterial), antifungal (voriconazole or posaconazole) — recommended by ASH 2026 guidelines [30]
Definitive therapy (hematology-directed)
- Hematopoietic stem cell transplant (HSCT):
- First-line for patients <40 years with a matched sibling donor (MSD) [15]
- For patients <20–40 years, matched unrelated donor (MUD) HSCT is also an option [15]
- For patients >40 years, IST is generally preferred over transplant [1][15]
- Immunosuppressive therapy (IST):
- Horse ATG + cyclosporine + eltrombopag (triple therapy) is the current standard for patients not proceeding to upfront HSCT [1][26][30]
- Response rate ~70–80% with IST-eltrombopag [28]
- Eltrombopag (TPO-receptor agonist) added to IST improves hematologic response [1]
- Growth factor support: G-CSF for severe neutropenia; thrombopoietin mimetics (eltrombopag, romiplostim) [7]
- ICI-related aplastic anemia: Discontinue immunotherapy; prednisone/methylprednisolone 1–2 mg/kg/day; if no response in 7 days, consider IVIG, cyclosporine, ATG [7]
17. Disposition
- Admit (typically to hematology/oncology service):
- Severe or very severe aplastic anemia (ANC <0.5 × 10⁹/L, platelets <20 × 10⁹/L)
- Febrile neutropenia
- Active hemorrhage
- Hemodynamic instability
- New diagnosis requiring urgent bone marrow biopsy and initiation of therapy
- ICU admission: Septic shock, massive hemorrhage, intracranial hemorrhage, respiratory failure
- Observation: Mild/non-severe aplastic anemia with stable counts and no active infection or bleeding may be managed outpatient with close hematology follow-up [4]
- Specialist consultation triggers: Hematology (all cases), transplant team (early HLA typing for eligible patients), infectious disease (invasive fungal infection), hepatology (hepatitis-associated AA)
18. Follow Up / Return Precautions
- Follow-up timing: CBC monitoring at least 2–3 times per week during acute phase; weekly to biweekly once stabilized
- Symptoms requiring immediate reassessment:
- Fever ≥38°C (100.4°F) — treat as emergency
- New or worsening bleeding (especially gums, nose, GI, or headache suggesting intracranial hemorrhage)
- Severe fatigue, dizziness, syncope, chest pain (worsening anemia)
- Dyspnea, cough (pneumonia, pulmonary hemorrhage)
- Patient counseling:
- Strict hand hygiene, avoid sick contacts, avoid crowds
- No contact sports or activities with bleeding risk
- No aspirin, NSAIDs, or IM injections
- Use soft toothbrush, electric razor
- Report any fever immediately — do not take antipyretics before calling
- Expected recovery course: Response to IST typically takes 3–6 months; transplant engraftment occurs in 2–4 weeks but full immune reconstitution takes months. Relapse after IST occurs in ~30–40% of patients, and clonal evolution to MDS/AML occurs in 10–15% long-term. [1][3][28-29][31]
Images
References
1. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. — Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. The New England Journal of Medicine. 2022.
2. Aplastic Anemia: History and Recent Developments in Diagnosis and Treatment. — Onishi Y. International Journal of Hematology. 2024.
3. Revisiting Acquired Aplastic Anaemia: Current Concepts in Diagnosis and Management. — Clucas DB, Fox LC, Wood EM, et al. Internal Medicine Journal. 2019.
4. Aplastic Anaemia. — Brodsky RA, Jones RJ. Lancet. 2005.
5. The Pathophysiology of Acquired Aplastic Anemia. — Young NS, Maciejewski J. The New England Journal of Medicine. 1997.
6. Aplastic Anemia. — Young NS. The New England Journal of Medicine. 2018.
7. Management of Immune Checkpoint Inhibitor-Related Toxicities. — Updated 2025-10-23. National Comprehensive Cancer Network.
8. Acute Severe Cholestatic Hepatitis and Lymphopenia Characterize Pediatric Hepatitis-Associated Aplastic Anemia. — Tegtmeyer D, Tsaka S, Lehmberg K, et al. Journal of Pediatric Gastroenterology and Nutrition. 2025.
9. Hepatitis Associated Aplastic Anemia: A Review. — Rauff B, Idrees M, Shah SA, et al. Virology Journal. 2011.
10. Pharmacovigilance Assessment of Drug-Induced Aplastic Anemia: Analysis of the FDA Adverse Event Reporting System. — Zhang F, Wang P, Liu X, Chen Y, Yang J. International Journal of Clinical Pharmacy. 2025.
11. The Relationship of Drug Therapy to Aplastic Anemia in Pakistan: A Hospital-Based Case Control Study. — Syed MA, Atta Ur Rahman A, Shah Syed MN, Memon NM. Therapeutics and Clinical Risk Management. 2021.
12. Epidemiology of Aplastic Anemia in France: A Case-Control Study. I. Medical History and Medication Use. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. — Baumelou E, Guiguet M, Mary JY. Blood. 1993.
13. Myelodysplastic Syndromes. — Updated 2026-01-12. National Comprehensive Cancer Network.
14. Pancytopenia Secondary to Vitamin B12 Deficiency in Older Subjects. — Costanzo G, Sambugaro G, Mandis G, Vassallo S, Scuteri A. Journal of Clinical Medicine. 2023.
15. ASH Clinical Practice Guidelines on Aplastic Anemia. — American Society of Hematology (2025). 2025.
16. Neutropenia: Evaluation and Management in the Primary Care Setting. — Kim MJ, Forlini C, Kremsreiter K. American Family Physician. 2025.
17. Immuno-Microbial Crosstalk in Aplastic Anemia: Role of Gut and Viral Triggers. — Mohit, Verma S, Venkatesh V, Nityanand S. Microbial Pathogenesis. 2025.
18. Concise Review: Anemia Caused by Viruses. — Morinet F, Leruez-Ville M, Pillet S, Fichelson S. Stem Cells. 2011.
19. Incidence and Risk Factors of Aplastic Anemia in Latin American Countries: The LATIN Case-Control Study. — Maluf E, Hamerschlak N, Cavalcanti AB, et al. Haematologica. 2009.
20. Low Drug Attributability of Aplastic Anemia in Thailand. The Aplastic Anemia Study Group. — Issaragrisil S, Kaufman DW, Anderson T, et al. Blood. 1997.
21. Red Cells II: Acquired Anaemias and Polycythaemia. — Provan D, Weatherall D. Lancet. 2000.
22. Myelodysplastic Syndromes. — Adès L, Itzykson R, Fenaux P. Lancet. 2014.
23. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. — Sekeres MA, Taylor J. The Journal of the American Medical Association. 2022.
24. New Onset Pancytopenia in Adults: A Review of Underlying Pathologies and Their Associated Clinical and Laboratory Findings. — Devitt KA, Lunde JH, Lewis MR. Leukemia & Lymphoma. 2014.
25. Pathophysiology and Clinical Outcomes of Pancytopenia in Disseminated Histoplasmosis: A Scoping Review. — Ekeng BE, Elem DE, Kokelu AN, et al. Infection. 2025.
26. Initial Management of Patients With Acquired Aplastic Anemia in the United States: Results From a Large National Claims Database. — Stempel JM, Wang R, Lee AI, et al. Annals of Hematology. 2025.
27. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
28. Clonal Selection and Evolution after Treatment of Severe Aplastic Anemia. — Gutierrez-Rodrigues F, Groarke EM, Miao R, et al. NEJM Evidence. 2026.
29. Haploidentical Bone Marrow Transplantation in Patients With Relapsed or Refractory Severe Aplastic Anaemia in the USA (BMT CTN 1502): A Multicentre, Single-Arm, Phase 2 Trial. — DeZern AE, Eapen M, Wu J, et al. The Lancet. Haematology. 2022.
30. American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia. — Scheinberg P, O'Neal DA, Basquiera AL, et al. Blood Advances. 2026.
31. How I Treat Acquired Aplastic Anemia. — Bacigalupo A. Blood. 2017.